Bradykinin is a physiologically and pharmacologically active peptide of the kinin group of proteins, consisting of nine amino acids.
CAT No: 10-101-72
CAS No: 6846-03-3
Synonyms/Alias: Bradykinin acetate salt;6846-03-3;Bradykinin Acetate;BRADYKININ, ACETATE SALT, 98;acetic acid;(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;H 1970; (S)-2-((S)-2-((S)-1-((S)-2-((S)-2-(2-((S)-1-((S)-1-((S)-2-Amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5-guanidinopentanoic Acid;L-BRADYKININ; ACETIC ACID;VIGBULRGBBKXHS-MIEKKPBHSA-N;MFCD06763566;AS-78097;PD018630;E78596;Bradykinin acetate (H-L-Arg-L-Pro-L-Pro-Gly-L-Phe-L-Ser-L-Pro-L-Phe-L-Arg-OH.CH3CO2H);
Chemical Name: acetic acid;(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C52H77N15O13 |
M.W/Mr. | 1120.3 |
Sequence | One Letter Code:RPPGFSPFR Three Letter Code:H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH.CH3CO2H |
Application | The pharmacological properties of bradykinin include smooth muscle contraction, vasodilation and hypotension, increase in capillary permeability with edema formation and induction of pain. It induces broncoconstriction in asthmatic subjects and symptoms of rhinitis in nasal provocation. |
Appearance | white fine crystalline powder |
Length | 9 |
Long-term Storage Conditions | ≥113 mg/mL in DMSO with gentle warming; ≥113.5 mg/mL in EtOH with gentle warming; ≥226.6 mg/mL in H2O |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C50H73N15O11.C2H4O2/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55;1-2(3)4/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57);1H3,(H,3,4)/t32-,33-,34-,35-,36-,37-,38-,39-;/m0./s1 |
InChI Key | VIGBULRGBBKXHS-MIEKKPBHSA-N |
Canonical SMILES | CC(=O)O.C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O |
Isomeric SMILES | CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O |
2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
3. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.